Literature DB >> 7704950

Excess matrix accumulation in scleroderma is caused partly by differential regulation of stromelysin and TIMP-1 synthesis.

G Bou-Gharios1, J Osman, C Black, I Olsen.   

Abstract

Scleroderma (systemic sclerosis: SSc) is an autoimmune disorder in which excessive extracellular matrix is deposited in skin and internal organs. Because of the importance of metalloproteinases in the turnover of connective tissue, in this study we have developed a novel procedure which utilises flow cytometry (FACS) to measure the production of stromelysin (MMP-3), gelatinase A (MMP-2), and the proteinase inhibitor TIMP-1, by SSc skin fibroblasts. In the presence of monensin, which prevents the secretion of these matrix proteins, there was a similar intracellular accumulation of gelatinase A in normal and SSc cells. However, whereas stromelysin levels also increased in the normal cells, no net synthesis could be detected in the SSc fibroblasts. In marked contrast, the synthesis of TIMP-1 was 50% greater in the SSc cells than in the normal fibroblasts. Our results thus show unequivocally, for the first time, that cells from SSc patients simultaneously produce less stromelysin but substantially higher amounts of TIMP-1 than do normal dermal fibroblasts, suggesting that abnormalities in the regulation of the matrix enzymes and their inhibitors play an important part in the molecular pathology of SSc.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7704950     DOI: 10.1016/0009-8981(94)90255-0

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  11 in total

1.  Collagen turnover is diminished by different clones of skin fibroblasts from early- but not late-stage systemic sclerosis.

Authors:  Camilo S Zurita-Salinas; Edgar Krötzsch; Lino Díaz de León; Jorge Alcocer-Varela
Journal:  Rheumatol Int       Date:  2003-11-05       Impact factor: 2.631

2.  Analysis of TIMP-1 gene polymorphisms in Italian sclerodermic patients.

Authors:  Manuela Indelicato; Valentina Chiarenza; Massimo Libra; Grazia Malaponte; Valentina Bevelacqua; Maurizio Marchini; James A McCubrey; Franca Stivala; Raffaella Scorza; Maria Clorinda Mazzarino
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

3.  MMP- and TIMP-secretion by human cutaneous keratinocytes and fibroblasts--impact of coculture and hydration.

Authors:  Andrea A Tandara; Thomas A Mustoe
Journal:  J Plast Reconstr Aesthet Surg       Date:  2010-06-09       Impact factor: 2.740

4.  Age-dependent loss of MMP-3 in Hutchinson-Gilford progeria syndrome.

Authors:  Ingrid A Harten; Rima S Zahr; Joan M Lemire; Jason T Machan; Marsha A Moses; Robert J Doiron; Adam S Curatolo; Frank G Rothman; Thomas N Wight; Bryan P Toole; Leslie B Gordon
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2011-08-17       Impact factor: 6.053

5.  Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.

Authors:  S A Young-Min; C Beeton; R Laughton; T Plumpton; S Bartram; G Murphy; C Black; T E Cawston
Journal:  Ann Rheum Dis       Date:  2001-09       Impact factor: 19.103

6.  Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis.

Authors:  C Nishijima; I Hayakawa; T Matsushita; K Komura; M Hasegawa; K Takehara; S Sato
Journal:  Clin Exp Immunol       Date:  2004-11       Impact factor: 4.330

7.  High doses of TGF-β potently suppress type I collagen via the transcription factor CUX1.

Authors:  Maria Fragiadaki; Tetsurou Ikeda; Abigail Witherden; Roger M Mason; David Abraham; George Bou-Gharios
Journal:  Mol Biol Cell       Date:  2011-04-06       Impact factor: 4.138

8.  Plasma Glycosaminoglycan Profiles in Systemic Sclerosis: Associations with MMP-3, MMP-10, TIMP-1, TIMP-2, and TGF-Beta.

Authors:  Kornelia Kuźnik-Trocha; Katarzyna Winsz-Szczotka; Katarzyna Komosińska-Vassev; Agnieszka Jura-Półtorak; Anna Kotulska-Kucharz; Eugeniusz J Kucharz; Przemysław Kotyla; Krystyna Olczyk
Journal:  Biomed Res Int       Date:  2020-04-21       Impact factor: 3.411

9.  Circulating tissue inhibitor of matrix metalloproteinase-4 (TIMP-4) in systemic sclerosis patients with elevated pulmonary arterial pressure.

Authors:  Gialafos J Elias; Moyssakis Ioannis; Psaltopoulou Theodora; Papadopoulos P Dimitrios; Perea Despoina; Vlasis Kostantinos; Kostopoulos Charalampos; Votteas Vassilios; Sfikakis P Petros
Journal:  Mediators Inflamm       Date:  2009-01-25       Impact factor: 4.711

10.  Cells from the skin of patients with systemic sclerosis secrete chitinase 3-like protein 1.

Authors:  Yuen Yee Ho; Murray Baron; Anneliese D Recklies; Peter J Roughley; John S Mort
Journal:  BBA Clin       Date:  2014-01-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.